|
By George D Henderson (AHCS)
I have found that pancreatic cancer that has metastasased to liver
cancer can be reversed with intravenous alpha-lipoic acid and low-dose
naltrexone. The guy is still alive in 2006 after being told in 2002 he
would die soon, he is back at work and other people are surviving on
the protocol.
The low-dose naltrexone can also beat B-cell lymphoma. This is pretty good news for people with alpha lipoic acid on hep C.
Never Say Die; say "Intravenous Alpha Lipoic Acid and Low Dose Naltrexone"
Medical
cancer tends to write off the cancer pantient with liver metastases.
This guy should have died in 2002, but went back to work instead and
was still working in 2006 when the paper was written. A B-cell
lymphoma, a cancer of the immune system, was also succesfully treated.
Treatment With the Intravenous -Lipoic Acid/Low-Dose Naltrexone Protocol
Burton M. Berkson
Integrative Medical Center of New Mexico and New Mexico State University, Las Cruces
Daniel M. Rubin
Scottsdale, Arizona,
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Arthur J. Berkson
Department of Family Practice, University of Illinois at Chicago, Illinois Masonic Medical Center, and the Department of Family Practice, Advocate Health Center, Chicago, Illinois
The authors describe the long-term survival of a patient with pancreatic cancer without any toxic adverse effects. The treatment regimen includes the intravenous -lipoic acid and low-dose naltrexone (ALA-N) protocol and a healthy lifestyle program. The patient was told by a reputable university oncology center in October 2002 that there was little hope for his survival. Today, January 2006, however, he is back at work, free from symptoms, and without appreciable progression of his malignancy. The integrative protocol described in this article may have the possibility of extending the life of a patient who would be customarily considered to be terminal. The authors believe that life scientists will one day develop a cure for metastatic pancreatic cancer, perhaps via gene therapy or another biological platform. But until such protocols come to market, the ALA-N protocol should be studied and considered, given its lack of toxicity at levels reported. Several other patients are on this treatment protocol and appear to be doing well at this time.
Key Words: pancreatic cancer • naltrexone • lipoic acid • survival
Burton
Berkson designed the equally succesful Triple Antioxidant therapy for
Hep C, using alpha lipoic acid, selenium, and silymarin.
Here is a summary of his work from Wikipedia:
The
first human clinical studies using alpha-lipoic acid (ALA) in the
United States were carried out by Fredrick C. Bartter, Burton M.
Berkson, and associates from the National Institutes of Health in the
1970's.[7][8][9]
They administered intravenous ALA to 79 people with acute and severe
liver damage at various medical centers across the United States and 75
recovered full liver function. Dr.'s Bartter and Berkson were appointed
by the FDA as principal investigators for this therapeutic agent as an
investigational drug and Dr. Berkson went on to use it successfully for
the treatment of chronic liver disease (viral hepatitis, autoimmune
hepatitis, etc).[10]
In
addition, because of ALA's ability to modify gene expression by
stabilizing NF kappa B transcription factor, Berkson started using ALA
for the treatment of various cancers for which no effective treatments
exist. In a 2006 publication, he and co-authors described the long term
survival of a patient with metastatic pancreatic cancer using ALA and
various oral antioxidants.[11]
A 2007 publication of a case study described the complete reversal of
the signs and symptoms of a B-cell lymphoma in a patient using less
than one month of IV ALA and 6 months of low dose naltrexone. [12]
- ^
Berkson, BM. "Thioctic Acid in the Treatment of Poisoning with Alpha
amanitin." Amanita Toxins and Poisonings, 1980. Amanita Toxins and
Poisonings, 203 (Heidelberg: International Amanita Symposium, Nov. 1-3,
1978). eds Faulstich, H., Kommerell, B., and Th. Wieland, Verlag
Gerhard Witzstrock, Baden-Baden, Koln, New York 1980.
- ^
Berkson, B. 1979. Thioctic acid in treatment of hepatotoxic mushroom
poisoning (letter). New England Journal of Medicine. 300:371.
- ^
Bartter FC, Berkson BM, Gallelli J and Hiranaka P. "Treatment of Four
Delayed-Mushroom-Poisoning Patients with Thioctic Acid." in Amanita
Toxins and Poisonings, eds Faulstich, H., Kommerell, B., and T.Wieland,
Verlag Gerhard Witzstrock, Baden-Baden, New York 1980.
- ^
Berkson BM. "A Conservative Triple Antioxidant Approach to the
Treatment of Hepatitis C. Combination of Alpha-Lipoic Acid (Thioctic
Acid), Silymarin and Selenium. Three Case Histories." Medizinische
Klinik 94(3), 1999: 84-89.
- ^
Berkson, BM, Rubin D, and Berkson AJ "Long term survival of a 46 year
old man with pancreatic cancer and liver metastases and treated with
intravenous alpha lipoic acid and low dose naltrexone" Integrative
Cancer Therapies 5;1 March 2006,83-89
- ^
Burton M. Berkson, Daniel M. Rubin and Arthur J. Berkson [Reversal of
Signs and Symptoms of a B-cell lymphoma in a patient using only
low-dose naltrexone Integrative Cancer Therapies 6(3); September 2007, 293-296 DOI: 10.1177/1534735407306358
Add this page to your favourite Social Bookmarking websites;        
 
 |
